No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 2,562 | 4,469 | 8,738 | 5,407 | 4,166 | 4,191 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 132 | 774 | 2,160 | 518 | -309 | 56 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
MRT Inc. operates a medical information platform. It provides Gaikin, a recruitment service specializing in part-time physicians; career, a job change support service for doctors; re:ray, a one stop outsourcing service; Door., an app to connect network of doctors; Door.into, an app platform that connects doctors and medical institutions with individuals; Pocket Doctor, a telemedicine app; groupware for medical departments; and FASTCALL a safety confirmation service for medical institutions consolidating the functions for hospital crisis management systems. The company also offers stem cell culture supernatant for medical institutions; pharmacist, clinical engineering technician, radiologic technologists, dialysis nurses, new practice openings and succession cases, clinical laboratory technician, and nurse recruitment services; job posting service for full-time and part-time industrial physicians; occupational health services; employment placement services; life support services; and full-time, part-time, and temporary positions for healthcare and welfare professionals. In addition, it engages in book publishing on illness and treatment; medical worker job placement business; business start-up; business succession support business; PR services, comprehensive membership compensation system, tax accountant referral services, and human umbilical cord-derived culture supernatant. Further, it offers anew, a service aimed at payroll calculation for doctors part-time jobs and payroll transfer agency services; Medikiki, an information distribution platform connecting manufacturers and wholesalers; and Kids Line that provides babysitting services. MRT Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
MRT Inc. operates a medical information platform. It provides Gaikin, a recruitment service specializing in part-time physicians; career, a job change support service for doctors; re:ray, a one stop outsourcing service; Door., an app to connect network of doctors; Door.into, an app platform that connects doctors and medical institutions with individuals; Pocket Doctor, a telemedicine app; groupware for medical departments; and FASTCALL a safety confirmation service for medical institutions consolidating the functions for hospital crisis management systems. The company also offers stem cell culture supernatant for medical institutions; pharmacist, clinical engineering technician, radiologic technologists, dialysis nurses, new practice openings and succession cases, clinical laboratory technician, and nurse recruitment services; job posting service for full-time and part-time industrial physicians; occupational health services; employment placement services; life support services; and full-time, part-time, and temporary positions for healthcare and welfare professionals. In addition, it engages in book publishing on illness and treatment; medical worker job placement business; business start-up; business succession support business; PR services, comprehensive membership compensation system, tax accountant referral services, and human umbilical cord-derived culture supernatant. Further, it offers anew, a service aimed at payroll calculation for doctors part-time jobs and payroll transfer agency services; Medikiki, an information distribution platform connecting manufacturers and wholesalers; and Kids Line that provides babysitting services. MRT Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.